60 Degrees Pharmaceuticals, Inc.

SXTP • Biotechnology

Movimiento fuerte

SXTP+11.47%

vs. cierre anterior $0.83

$0.92

▲ +0.09 (+11.47%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$2.40M

Crecimiento

-0.1%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 16.9%Nivel de deuda manejable · 0.04Liquidez saludable · 2.66Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:24 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.92

Change11.47%

Shares Out2.65M

Market Cap$2.40M

Enterprise Value$1.38M

52W Range1.05 - 8.62

Beta2.54

P/E-0.30

P/S2.16

P/B0.95

P/FCF-0.62

EV/Sales1.24

Price$0.92

Change11.47%

Shares Out2.65M

Market Cap$2.40M

Enterprise Value$1.38M

52W Range1.05 - 8.62

Beta2.54

P/E-0.30

P/S2.16

P/B0.95

P/FCF-0.62

EV/Sales1.24

EV/EBITDA-0.17

EV/FCF-0.35

Earnings Yield-337.42%

FCF Yield-162.47%

Dividend Yield0.00%

Gross Margin22.26%

Oper. Margin-7.72%

Profit Margin-7.33%

Debt/Eq0.04

Current Ratio2.66

Quick Ratio2.30

Revenue 5Y-0.12%

Volume140.75K

Avg Volume118.94K

EPS Surprise-0.52

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

94/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 16.9%Nivel de deuda manejable · 0.04Liquidez saludable · 2.66Rentabilidad débil

Analyst view

Analyst sentiment and price target

SXTP

Analyst sentiment

Based on 2 analyst votes · 2026-10-20

75/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 7/12/2023

Industria: Biotechnology

P/B i: 0.95

Deuda / Patrimonio i: 0.04

Margen operativo: -771.64%

Margen neto: -732.82%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.04

Ratio corriente: 2.66

Ratio rápido: 2.30

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Knight Therapeutics Inc.

Transacción: 07/22/2026

OTRO

Cambio

Precio

Not reported

Presentación

07/29/2026

Tipo

OTRO

DOW GEOFFREY S

Transacción: 06/12/2026

COMPRA

Cambio

+7,350

Precio

$1.38

Presentación

06/15/2026

Tipo

COMPRA

Francois Eric

Transacción: 05/13/2026

OTRO

Cambio

Precio

Not reported

Presentación

05/19/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Knight Therapeutics Inc.	OTRO	0	Not reported	07/22/2026	07/29/2026
DOW GEOFFREY S	COMPRA	+7,350	$1.38	06/12/2026	06/15/2026
Francois Eric	OTRO	0	Not reported	05/13/2026	05/19/2026
DOW GEOFFREY S	COMPRA	+9,670	$0.80	12/15/2025	12/16/2025
DOW GEOFFREY S	COMPRA	+3,613	$0.92	12/11/2025	12/12/2025
DOW GEOFFREY S	COMPRA	+9,350	$0.95	12/10/2025	12/12/2025
DOW GEOFFREY S	COMPRA	+7,201	$1.39	09/12/2025	09/15/2025
Landon Kristen	COMPRA	+4,540	Not reported	01/17/2025	08/14/2025
Landon Kristen	COMPRA	+4,167	$6.85	09/26/2024	08/14/2025
Landon Kristen	OTRO	0	Not reported	02/12/2024	08/14/2025
DOW GEOFFREY S	COMPRA	+4,376	$2.99	06/09/2025	06/09/2025
XU CHERYL	COMPRA	+3,000	$2.87	06/03/2025	06/05/2025
MILLER TYRONE	COMPRA	+75,000	$1.31	01/02/2025	01/24/2025
DOW GEOFFREY S	COMPRA	+525,000	$1.31	01/02/2025	01/24/2025
MILLER TYRONE	COMPRA	+11,626	Not reported	01/17/2025	01/21/2025
DOW GEOFFREY S	COMPRA	+14,394	Not reported	01/17/2025	01/21/2025
XU CHERYL	COMPRA	+2,000	$1.45	12/16/2024	12/18/2024
XU CHERYL	COMPRA	+1,500	$1.60	12/13/2024	12/18/2024
XU CHERYL	COMPRA	+2,500	$1.85	12/12/2024	12/18/2024
DOW GEOFFREY S	COMPRA	+35,823	$1.27	12/09/2024	12/09/2024

Sobre la compañía

60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.

Fuente - Link

Competidores

BDRX CANF CLDI CMND CNSP GRI JAGX KZIA SILO SNGX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation. Profitability This table compares Eyepoint Pharmaceuticals

Defense World

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded As of the same date, the Company had enrolled 30 patients Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027 No safety signals were identified in the study Published case reports and the Company's prospective expanded access study support the potential of tafenoquine-containing regimens in treatment-refractory, relapsing babesiosis, and additional data will be disclosed from this study in early November 2026 Company sees a viable regulatory pathway for severe and/or treatment-refractory disease and will request a pre-sNDA meeting with FDA in January 2027 to discuss data requirements, patient population, regulatory pathway, and post-marketing requirements WASHINGTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it intends to conclude enrollment in its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis at 30 subjects.

GlobeNewsWire

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis ( NCT06207370 ) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

GlobeNewsWire

Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Innoviva (NASDAQ: INVA - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Institutional and Insider Ownership 99.1% of Innoviva

Defense World

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

60 Degrees Pharma (Nasdaq: SXTP) will present on demand at H.C. Wainwright beginning Sept. 11 and hold 1 x 1 investor meetings Sept. 14–16 in New York.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-15	-0.76	-1.28	-0.52
2026-03-26	-2.28	-1.69	0.59
2025-11-13	-1.84	-2.64	-0.8
2025-08-13	-1.24	-1.25	-0.01
2025-05-15	-1.31	-1.56	-0.25
2025-03-27	-4.01	-14.2	-10.19
2024-11-14	-3	-4.65	-1.65
2024-08-14	-19.8	-21.15	-1.35
2024-05-15	-9.6	1.8	11.4
2024-04-01	-16.21	-26.41	-10.2
2023-11-20	-15.61	-18.01	-2.4